Antibody-based therapies for HCC, lung squamous cell carcinoma (LSCC) and other GPC3-expressed solid tumors are being investigated in preclinical and clinical studies, and several clinical trials using GPC3-targeted CAR-T cells are underway as well. This evidence concerns the gene GPC3 and squamous cell lung carcinoma.